Equity Analysis /

MY : Optimax Holdings - Healthy underlying demand in 1Q & beyond

    26 May 2022
    Published by

    1Q22 core EPS was in line, doubling yoy on strong revenue growth. Broad-based growth in number of surgeries bodes well for future earnings. Reiterate Add and RM0.77 TP (28x CY23F P/E). We continue to like Optimax for its strong earnings growth prospects (FY21-24F core EPS CAGR: 18.2%).